Vertex Pharmaceuticals Reports 12% Revenue Growth Driven by Alyftrek Transition
Vertex Pharmaceuticals (VRTX) reported third-quarter revenue of $3.44 billion, a 12% increase year-over-year. This growth was primarily driven by the successful transition within its cystic fibrosis franchise, as patients shifted from Trikafta to the once-daily Alyftrek, which generated $706 million in revenue. Non-cystic fibrosis revenue also saw significant expansion, rising to $168 million. Despite strong sales, adjusted profit remained largely flat due to heavy investment in new product launches and the acquisition of Crinetics. The company is currently absorbing high launch costs for various pipeline products and building out sales teams ahead of upcoming regulatory decisions. Investors are now looking toward a critical FDA decision on November 30 regarding its kidney drug, povetacicept.